News
LEGN
18.54
-5.12%
-1.00
Legend Biotech (LEGN) Could Be 57% Undervalued On Profitability And CARVYKTI Growth
Simply Wall St · 20h ago
Legend Biotech Is Maintained at Perform by Oppenheimer
Dow Jones · 1d ago
Legend Biotech Price Target Cut to $25.00/Share From $40.00 by Oppenheimer
Dow Jones · 1d ago
Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25
Benzinga · 1d ago
Legend Biotech Price Target Cut to $43.00/Share From $49.00 by Morgan Stanley
Dow Jones · 1d ago
Legend Biotech Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $43
Benzinga · 1d ago
Legend Biotech Price Target Cut to $61.00/Share From $68.00 by Barclays
Dow Jones · 1d ago
Legend Biotech Is Maintained at Overweight by Barclays
Dow Jones · 1d ago
Legend Biotech Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
Legend Biotech Price Target Cut to $50.00/Share From $56.00 by RBC Capital
Dow Jones · 1d ago
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $61
Benzinga · 1d ago
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $50
Benzinga · 1d ago
Legend Biotech price target lowered to $50 from $56 at RBC Capital
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: REPRO-MED Systems (KRMD), Legend Biotech (LEGN) and TELA Bio (TELA)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Universal Health (UHS) and Legend Biotech (LEGN)
TipRanks · 1d ago
Legend Biotech price target lowered to $43 from $49 at Morgan Stanley
TipRanks · 1d ago
Legend Biotech price target lowered to $25 from $40 at Oppenheimer
TipRanks · 1d ago
Analysts’ Top Healthcare Picks: Protalix (PLX), Legend Biotech (LEGN)
TipRanks · 1d ago
Legend Biotech price target lowered to $61 from $68 at Barclays
TipRanks · 1d ago
More
Webull provides a variety of real-time LEGN stock news. You can receive the latest news about Legend Biotech Corp through multiple platforms. This information may help you make smarter investment decisions.
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.